<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363619</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01524</org_study_id>
    <nct_id>NCT04363619</nct_id>
  </id_info>
  <brief_title>Insights From the Retina on Cerebral Microvascular Dysfunction in Haemorrhagic Stroke</brief_title>
  <acronym>RETINA-ICH</acronym>
  <official_title>Insights From the Retina on Cerebral Microvascular Dysfunction in Haemorrhagic Stroke. A Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fundoscopy, optical coherence tomography (OCT) and OCT-angiography (OCTA) are established
      examinations and bear minimal risks. The recognition of retinal microvascular signs will
      enhance the pathophysiological understanding of the vasculopathy in patients with
      intracerebral haemorrhage (ICH) and aneurysmatic subarachnoid hemorrhage (aSAH) and might
      serve as prognostic and diagnostic indicators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to

        -  To evaluate the feasibility of fundoscopy, OCT and OCTA imaging in the environment of a
           Neurocritical Care Unit (NCCU)

        -  To detect, quantify and associate microvascular changes in the retina with signs of
           micro-vessel disease in ICH and DCI in aSAH
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>i. Number of fundus photography, OCT, and OCTA examinations with usable and quantifiable results.</measure>
    <time_frame>From hospital entry up to 3-6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ICH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aSAH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OCT and OCTA</intervention_name>
    <description>Fundoscopy, OCT and OCTA will be performed 4 times in patients</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>ICH</arm_group_label>
    <arm_group_label>aSAH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All groups

               -  Primary ICH or aSAH with symptoms onset &lt; 3 days

               -  18 to unlimited years of age

               -  Signed informed consent obtained from legal representative or patient ICH group

               -  Primary ICH localized either in basal ganglia, thalamus, pons or cerebellum aSAH
                  group

               -  Ruptured aneurysm visualized in contrast-enhanced computed tomography (angio-CT),
                  MRI or cerebral angiography Control group

               -  Stroke due to perimesencepahlic subarachnoid hemorrhage, arteriovenous
                  malformation or isolated traumatic brain injury

        Exclusion Criteria:

          -  All groups

               -  Cerebral amyloid angiopathy or other neurodegenerative disease

               -  History of migraine with aura or ischemic stroke

               -  Contraindication for pupil dilation (intracranial hypertension, allergy against
                  mydriatics, angle closure glaucoma)

               -  Any pre-existing or manifest ocular condition affecting either the integrity of
                  retinal vessels, transparency of optical media or the risk of acute angle closure
                  glaucoma

               -  Concomitant instable critical illness (e.g. sepsis, multi-organ failure)

               -  Intracranial pressure &gt; 20mmHg and refractory to cerebrospinal fluid drainage

               -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Emanuela Keller</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

